Patrick Moore, MD
Hematology/Oncology · Coal City
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Offices
- 3
Offices
3 locations · Riverside Health System · 202 clinicians in this group
Hospitals listed: Yuma Regional Medical Center. That is not proof they admit you there this week.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Moore’s office to ask if they take your plan before you enroll.
State licence records
1 licence
- Illinois 036150357Licensed Physician And Surgeon · since 2019 · expires 2029-07-31ActiveNo board action on this licenceCheck it with the state
We check Colorado, Delaware, Florida, Illinois, Maryland, New Jersey, New York, Tennessee, Texas, Virginia, Washington, plus California above. A state that is not in this list has not been checked, which is not the same as clear.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Yuma Regional Medical CenterYuma, AZAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Yuma Regional Medical CenterPatients rate it 3 of 5 · 63% would definitely recommend itOverall rating: 2 of 5 starsWorse than the national rate — Death rate among surgical inpatients with serious treatable complications: 223.03 (174.74 to 271.32) · 70 cases, Jul 2022 – Jun 2024Better than the national rate — Clostridium Difficile (C.Diff): 0.118, Oct 2024 – Sep 2025
See every measure and the patient survey for Yuma Regional Medical Center
Behind the star rating — Deaths: 0 better, 6 the same, 2 worse of 8 measures. Safety: 1 better, 7 the same, 0 worse of 8 measures. Readmissions: 0 better, 10 the same, 1 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 223.03 (174.74 to 271.32) · 70 cases | Worse | Jul 2022 – Jun 2024 |
| Clostridium Difficile (C.Diff)Infections | 0.118 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.49 (0.53 to 2.45) · 1,120 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.91 (0.59 to 1.24) | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 4 · 84 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 11.8 · 154 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 13.4 · 302 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 12.3 · 456 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 17.2 · 627 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 16 · 296 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 4.8 · 3,722 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.21 (0 to 0.42) · 5,914 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.23 (0.03 to 0.42) · 6,115 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 2.42 (0.37 to 4.48) · 1,577 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.43 (0 to 3.04) · 438 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.1 (0.65 to 3.55) · 1,494 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 10.77 (3.99 to 17.55) · 451 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.6 (1.75 to 9.45) · 415 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.63 (0.16 to 3.1) · 329 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.37 (0 to 1.06) · 4,890 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4 · 26 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.765 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.901 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.621 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.825 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 13.4 · 405 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 21.8 · 661 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -9.4 · 291 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 36.5 · 506 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 7 · 644 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 17.9 · 939 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 6.1 (4.5 to 8.3) · 327 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 12.6 (9.8 to 15.8) · 327 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission for CABGUnplanned return visits | 12.3 · 93 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.1 · 216 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 14 (11.2 to 17.3) · 2,778 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1.2 (0.9 to 1.4) · 940 cases | No different | Jan 2024 – Dec 2024 |
What patients said (1,342 patients answered, 22% of those asked)
| Cleanliness | 4 |
| Nurse communication | 2 |
| Doctor communication | 2 |
| Communication about medicines | 2 |
| Discharge information | 3 |
| Overall hospital rating | 2 |
| Quietness | 3 |
| Recommend hospital | 3 |
| Room was "always" clean | 73% |
| Nurses "always" communicated well | 73% |
| Doctors "always" communicated well | 72% |
| Staff "always" explained | 53% |
| Yes, staff "did" give patients this information | 83% |
| Yes, staff "did" give patients information about help after discharge | 82% |
| Doctors "always" explained things so they could understand | 66% |
| Doctors "always" listened carefully | 70% |
| Doctors "always" treated them with courtesy and respect | 79% |
| Patients who gave a rating of "9" or "10" (high) | 62% |
| Staff "always" explained new medications | 66% |
| Nurses "always" explained things so they could understand | 67% |
| Nurses "always" listened carefully | 69% |
| Nurses "always" treated them with courtesy and respect | 82% |
| "Always" quiet at night | 52% |
| "YES", patients would definitely recommend the hospital | 63% |
| Staff "always" explained possible side effects | 39% |
| Yes, staff "did" give patients information about possible symptoms | 83% |
Original Medicare doctor bills
$15,800
Medicare paid this office $15,800 for 41 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 20 | $6,044 | $101 |
| Long return visit (40+ min) | 16 | $5,316 | $121 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 13 | $2,348 | $147 |
Who their Medicare patients are
41 Original Medicare patients in 2024. Average age 66 · Women 51% · Also on Medicaid 39% · Health risk score 3.20. Sicker patients than 9 in 10 peers; the typical hematology-oncology clinician is at 2.04.
Conditions among them: High blood pressure 75% · Coronary heart disease 56% · Chronic kidney disease 44% · Diabetes 41% · Heart failure 34% · Depression 29%.
The office billed $42,961, Medicare allowed $19,693 and paid $15,800; for 138 services of 5 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 41 | 138 | 66 | 3.20 | $42,961 | $15,800 |
| 2022 | 14 | 14 | 74 | 1.84 | $13,033 | $2,510 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
Drugs they prescribed that Part D paid
$6,548
Pharmacies billed $6,548 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
73 generic and fewer than 11 brand-name prescriptions · $6,548 in drug cost · 13 antibiotic prescriptions.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Sulfamethoxazole-Trimethoprim | 12 | $48 | $4 |
Year by year
| 2024 | 79 | 11 | None | None | $6,548 |
| 2023 | 112 | 26 | None | None | $50,199 |
| 2022 | 54 | 19 | None | None | $11,798 |
| 2021 | 25 | None | None | None | $22,755 |
| 2020 | 85 | 30 | 0% (0) | 28% | $10,634 |
| 2019 | 616 | 82 | None | None | $69,680 |
| 2018 | 393 | 62 | None | 10% | $27,194 |
| 2017 | 442 | 66 | None | None | $34,485 |
| 2016 | 101 | 26 | None | 23% | $5,793 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 2 drugs
| Acyclovir | 16 | $765 | $48 |
| Sulfamethoxazole-Trimethoprim | 15 | $215 | $14 |
2022: 1 drug
| Anastrozole | 11 | $231 | $21 |
2019: 13 drugs
| Nifedipine Er | 12 | $561 | $47 |
| Atorvastatin | 42 | $496 | $12 |
| Felodipine Er | 12 | $367 | $31 |
| Omeprazole | 31 | $344 | $11 |
| Carvedilol | 32 | $251 | $8 |
| Hydralazine | 15 | $221 | $15 |
| Lisinopril | 30 | $213 | $7 |
| Amlodipine Besylate | 25 | $180 | $7 |
| Gabapentin | 24 | $153 | $6 |
| Trazodone | 22 | $142 | $6 |
| Pantoprazole | 11 | $107 | $10 |
| Hydrochlorothiazide | 11 | $58 | $5 |
| Metformin Hcl Er | 12 | $36 | $3 |
2018: 9 drugs
| Janumet Xr | 13 | $5,666 | $436 |
| Atorvastatin | 29 | $258 | $9 |
| Lisinopril | 35 | $241 | $7 |
| Hydrochlorothiazide | 18 | $140 | $8 |
| Gabapentin | 14 | $111 | $8 |
| Carvedilol | 18 | $98 | $5 |
| Amlodipine Besylate | 18 | $69 | $4 |
| Metoprolol | 13 | $63 | $5 |
| Sertraline | 11 | $47 | $4 |
2017: 12 drugs
| Humalog Kwikpen U-100 | 11 | $5,731 | $521 |
| Atorvastatin | 19 | $252 | $13 |
| Duloxetine | 12 | $188 | $16 |
| Lisinopril | 30 | $128 | $4 |
| Metformin | 12 | $123 | $10 |
| Amlodipine Besylate | 32 | $95 | $3 |
| Gabapentin | 11 | $88 | $8 |
| Hydrochlorothiazide | 11 | $78 | $7 |
| Pantoprazole | 12 | $63 | $5 |
| Carvedilol | 11 | $61 | $6 |
| Metoprolol | 13 | $53 | $4 |
| Metformin Hcl Er | 16 | $43 | $3 |
Money from drug and device companies
$156 in 2025
| 2025 | 1 | 1 | None | $156 |
| 2024 | 1 | 2 | None | $96 |
| 2022 | 2 | 2 | None | $222 |
| 2021 | 6 | 7 | None | $837 |
| 2020 | 1 | 1 | None | $113 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Janssen Scientific Affairs | Darzalex | $156 | 1 payment
|
See the published payment
| Janssen Scientific Affairs | Meals · 2025-02-28 | Darzalex | $156 |
See earlier years (2024, 2022, 2021, 2020)
2024: $96
| Janssen Scientific Affairs | Talvey | $96 | 2 payments
|
2022: $222
| Incyte | Jakafi | $120 | 1 payment
|
| E.R. Squibb & Sons L.L.C. | None | $103 | 1 payment
|
2021: $837
| Genzyme | Cablivi | $247 | 2 payments
|
| Incyte | Jakafi | $129 | 1 payment
|
| Jazz Pharmaceuticals | Vyxeos | $125 | 1 payment
|
| ADC Therapeutics America | None | $123 | 1 payment
|
| Celgene | Reblozyl | $113 | 1 payment
|
| Epizyme | Tazverik | $100 | 1 payment
|
2020: $113
| Pharmacyclics LLC An AbbVie | Imbruvica | $113 | 1 payment
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| Janssen Research & Development, LLC · Intermediate-Size Population Expanded Access Program (Eap) for Ciltacabtagene Autoleucel (Cilta-Cel) Out-of-Specification (Oos) in Patients With Multiple Myeloma · 2025 | Their institution | $20,840 |
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 97.7 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1639525371
- Licence
- IL 036.150357Illinois 036150357: Active
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207RH0003X (207RH0003X); Internal medicine (207R00000X); Hospitalist (208M00000X)
- Mailing address
- 1355 El Camino Real Unit 727, Redwood City, CA, 94063
- NPI first listed
- 2016-05-12
- NPI last updated
- 2025-09-17
- NPI record certified
- 2025-09-17
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 2375 S Ridgeview Dr, Yuma, AZ, 85364